Shares of Moderna Inc. MRNA, +5.95% gained 4.7% in trading on Friday after the company said that European regulators recommended authorizing its COVID-19 vaccine for teens as young as 12 years old. The European Medicines Agency's Committee for Medicinal Products for Human Use issued the recommendation; next up will be the final decision from the European Commission. Moderna's shot has not yet been authorized for teens in the U.S. The company's shares have soared 223.2% so far this year, while the S&P 500 SPX, +1.00% is up 16.3%.